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•Background: Androgen Receptor (AR) is the principle therapeutic target in prostate cancer. 
•Result: We have established that Usp12 deubiquitinates and stabilises the AR resulting in increased 
transcriptional and pro-proliferative activity. 
•Conclusion: We have identified Usp12 to be a novel positive regulator of AR. 
•Significance: Usp12 presents a therapeutic target upstream of AR that could enable bypassing the 
limitations of therapeutics aimed specifically at AR. 
SUMMARY 
The androgen receptor (AR), a member of 
the nuclear receptor family, is a 
transcription factor involved in prostate cell 
growth, homeostasis and transformation. 
AR is a key protein in growth and 
development of both normal and malignant 
prostate making it a common therapeutic 
target in prostate cancer (PCa). AR is 
regulated by an interplay of multiple post-
translational modifications including 
ubiquitination. We and others have shown 
that the AR is ubiquitinated by a number of 
E3 ubiquitin ligases, including MDM2, 
CHIP and NEDD4 which can result in its 
proteosomal degradation or enhanced 
transcriptional activity. As ubiquitination of 
AR causes a change in AR activity or 
stability and impacts both survival and 
growth of PCa cells, deubiquitination of 
these sites has an equally important role. 
Hence deubiquitinating enzymes (DUBs) 
could offer novel therapeutic targets. We 
performed an siRNA screen to identify 
DUBs that regulate AR, in that screen 
ubiquitin specific protease 12 (Usp12) was 
identified as a novel positive regulator of 
AR. Usp12 is a poorly characterised protein 
with few known functions and requires the 
interaction with two cofactors, Uaf-1 and 
WDR20, for its enzymatic activity. In this 
report we demonstrate that Usp12, in 
complex with Uaf-1 and WDR20, 
deubiquitinates the AR to enhance receptor 
stability and transcriptional activity. Our 
data shows that Usp12 acts in a pro-
proliferative manner by stabilising AR and 
enhancing its cellular function. 
The androgen receptor (AR) belongs to the 
nuclear hormone receptor superfamily, and 
plays a key role in the transcriptional 
regulation of numerous genes important in the 
development of both normal and malignant 
prostate [1]. Ligand binding of the AR in the 
cytoplasm results in dimerisation, 
translocation to the nucleus and transcription 
of androgen responsive genes. Deregulation of 
AR signalling leads to the development of 
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prostate cancer (PCa) and as such the receptor 
represents the most common therapeutic target 
in PCa [1]. The current clinical strategies in 
PCa centre around anti-hormone therapies and 
aim to pharmacologically decrease serum 
androgen levels. This is currently achieved  
through the  use of luteinising hormone-
releasing hormone (LHRH) agonists such as 
goserelin or anti-androgens which can be 
either steroidal (cyproterone acetate) or non-
steroidal (flutamide) and function by 
competitively inhibiting the AR [2]. However, 
despite initial success most of anti-androgen 
therapies will invariably fail resulting in 
castrate-resistant prostate cancer (CRPCa). 
Importantly, the AR signalling cascade 
remains functional in CRPCa. Treatment 
failure can be caused by changes in AR 
signalling including alterations in AR cofactor 
levels and activity as well as emergence of AR 
mutations that permit receptor activity in the 
presence of non-androgenic steroids and anti-
androgens [2]. In CRPCa, AR still remains a 
crucial target, with increased AR levels and 
gene amplification observed in 30% of 
patients. Increased levels of the downstream 
gene Prostate Specific Antigen (PSA) in the 
serum are also associated with PCa recurrence 
[3]. Previous research demonstrated that even 
at CRPCa stage, depletion of AR by siRNA 
treatment decreased tumor growth. Similarly, 
AR overexpression in PCa xenograft in 
castrate animals still enhanced cancer growth 
[4].  
AR function and activity is known to be 
regulated by a number of post-translational 
modifications. In response to androgens, AR is 
phosphorylated by kinases including AKT [5] 
and TFIIH [6] resulting in changes to 
transcriptional activity and cellular 
localisation. This can be reversed by 
phosphatases such as protein phosphatases 1 
and 2A [7]. Acetylation by p300 [8] and Tip60 
[9] enhances transcriptional activity which can 
be reversed by the histone deactylases HDAC1 
[10] and SIRT1 [11]. AR is also subjected to 
SUMOylation by PIAS1 and PIASxα, a 
process which is believed to decrease its 
transcriptional activity [12]. We and others 
have shown that the AR is also ubiquitinated 
by a number of E3 ubiquitin ligases, including 
MDM2 [13, 14], CHIP [15, 16] and NEDD4 
[17, 18] which results in proteosomal 
degradation. AR ubiquitination can also lead 
to the increase in transcriptional activity; 
RNF6 has been reported to ubiquitinate AR at 
K845 and K847 promoting its activity by 
allowing ARA54 co-activator recruitment 
[19]. Further details of AR post-translational 
modifications have been recently reviewed 
[20]. 
Ubiquitination of AR causes a change in AR 
activity and stability and impacts both survival 
and growth of PCa cells. As a result 
deubiquitination of those sites has an equally 
important role.  
Currently, very little is known about the 
enzymes that deubiquitinate AR. It has been 
reported that Usp26 can directly bind and 
deubiquitinate AR, acting as a co-regulator of 
AR by reversing AR activation and 
degradation by MDM2 ubiquitination 
depending on cellular context [21]. 
Additionally, Usp10 has been reported to bind 
AR resulting in increased transcriptional 
activity [22]. 
In this study we focused on Usp12, a 
deubiquitinating enzyme identified in an 
siRNA screen as a positive regulator of AR. 
Usp12 has three reported targets; histones 
H2B, H2A [23] and non-activated Notch [24]. 
Usp12 is highly homologous to Usp46 and 
Usp1 and its activity, similarly to that of 
Usp46, is enhanced by binding to its cofactors 
Uaf-1 and WDR20, with Uaf-1 required for 
enzymatic activity of Usp12 [25, 26, 27]. It 
has been reported that Uaf-1 binds and 
stabilises Usp12 and this complex is bound by 
WDR20. This interaction is both 
stoichiometric and evolutionarily conserved 
and has been shown to play the same role in S. 
pombe [28]. Usp12 and Uaf-1 containing 
complex was shown to deubiquitinate all types 
of ubiquitin chains apart from linear chains 
[27]. Our search of Oncomine profiles 
revealed that Usp12 is differentially expressed 
in bladder, brain, CNS, cervical, kidney, 
lymphoma and ovarian cancer samples 
compared to healthy controls. 
We now show that Usp12, in complex with 
Uaf-1 and WDR20, interacts with and 
deubiquitinates the AR resulting in increased 
protein stability and transcriptional activity. 
Moreover, we report that Usp12 depletion 
reduces PCa cell proliferation and up-regulates 
cell apoptosis suggesting it is an additional 
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regulator of the AR that may represent a novel 
target for therapy.  
EXPERIMENTAL PROCEDURES 
Antibodies and plasmids - Antibodies used 
were anti-Flag (Sigma), anti-Usp12 (Dundee 
Cell Products), anti-AR (Santa Cruz, N20 
clone), anti-HA (Santa Cruz, Y11 clone), anti-
α tubulin (Sigma) and anti-ubiquitin (Santa 
Cruz). Plasmids used were pPSA-Luc, 
pARE3-Luc, pCMV-β-gal, pFlag-His-AR [9], 
pFlag-Usp12 wild type and C48A mutant 
generated by in vitro mutagenesis 
(Quickchange, Stratagene), pHA-Ubiquitin 
and pHA-Flag-WDR20 and pFlag-Uaf-1 [25]; 
[26] which were kind gifts from Professor 
Alan D’Andrea (Dana-Farber Cancer Institute, 
Boston). 
Cell culture, transfections and reporter assays 
- LNCaP, HEK293T and COS-7 cells were 
obtained from American Type Culture 
Collection (Manassas, USA). VCaP cells were 
kindly donated by Professor Guido Jenster 
(Erasmus Medical Centre, Rotterdam). Cells 
were cultured in RPMI 1640 media with 2 mM 
L-glutamine (Invitrogen) supplemented with 
10% (v/v) foetal calf serum (FCS) at 37°C in 
5% CO2. LNCaP-AI variant cell line was 
derived in-house by culturing LNCaP cells in 
steroid-depleted media (DCC) to allow for the 
development of androgen independence [30]. 
LNCaP-7B7 cells stably overexpressing 
pPSA-Luc vector were kindly donated by 
Professor Jan Trapman (Erasmus Medical 
Centre, Rotterdam) and cultured with the 
addition of 25 µg/ml zeocin. Transfections 
were performed using TransIT-LT1 reagent 
(MirusBiol) following the manufacturer’s 
instructions.  
For luciferase assays, cells were transfected 
with 50 ng pARE3-luc, 50 ng pCMV-β-gal 
and 10 ng of pFlag-His-AR, pFlag-Usp12 and 
pFlag-Uaf-1 as required. All reactions were 
balanced with pCMV empty vector. Cells were 
cultured under steroid depleted conditions for 
48h followed by supplementation with 
dihydrotestosterone (DHT), at a range of 
concentration of 5 and 10 nM with comparable 
results obtained for both concentrations, for an 
additional 24h. Cells were lysed and incubated 
in 1x Promega luciferase assay reagents 
according to the manufacturer’s instruction 
and luciferase counts per second were 
established and normalised to β-galactosidase 
activity. Results were normalised to AR 
expression alone in steroid depleted 
conditions. 
siRNA gene silencing  and gene expression 
analysis - The generation and DUB siRNA 
screening methodology for AR regulators 
screen using an ELISA against PSA protein as 
a readout of AR activity in LNCaP cells has 
been described previously [29]. Usp12 
targeting siRNA sequences were (A) 
GAAACUCUGUGCAGUGAAU[dTdT] (B) 
CAGAUCUCUUCCAUAGCAU[dTdT] and 
(C) CAUCAGAUAUCUCAAAGAA[dTdT], 
WDR20 was silenced with siRNAs (A) 
CGAGAAAGAUCACAAGCGA[dTdT] and 
(B) GUUUGACCCUUAUACCACU[dTdT] 
and Uaf-1 with (A) 
CAAAUUGGUUCUCAGUAGA[dTdT] and 
(B) CAUUGACUGCCUCAAAUAA[dTdT]. 
Initial DUB screen used a pool of siRNAs 
against Usp12, further experiments were 
performed using siRNA (B). Uaf-1 A achieved 
61.5% knockdown with Uaf-1 B 61% 
similarly, WDR20 A achieved 67.4% and 
WDR20 B 57.4% in qPCR validation (data not 
shown). As a result siRNAs (A) were selected 
for silencing of both Uaf-1 and WDR20.   
LNCaP cells were reverse transfected with 
siRNA using RNAiMax (Invitrogen) 
according to manufacturer’s instructions and 
incubated in culture media for 96h prior to cell 
lysis and analysis by Western blotting as 
described previously [31] or qPCR. For qPCR 
RNA was extracted using the EZ RNA 
isolation kit (Biological Industries) and cDNA 
synthesis and data analysis was performed as 
described previously [32]. Proliferation was 
measured by cell counting 96h post gene 
silencing. To measure colony forming ability 
cells were reverse transfected with siRNA for 
72h, followed by re-seeding at varying cell 
densities and incubated for 14 days to allow 
colony formation and stained with crystal 
violet. Colonies were counted and the 
surviving fraction calculated [31]. 
Flow cytometry  - Cell cycle profiles were 
generated by propidium iodide (PI) staining, 
cells were permeabilised with 1% Triton X-
100 and incubated with 1 µg/ml RNaseA and 
PI followed by analysis on BD FACScan [33]. 
Levels of apoptosis were analysed after 96h of 
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gene silencing by Annexin V assay (BD) 
according to manufacturer’s instruction and 
analysed on BD FACScan. Cells were stained 
for both annexin V and PI positivity and 
during analysis divided into quarters 
representing normal cells, necrotic cells and 
apoptotic cells.  
Immunoprecipitations (IP) - Cells were seeded 
at  5x10
5
 cells per 90 mm dish, transfected 24h 
later with 1µg of each plasmid as indicated, 
incubated for 48h and lysed directly into lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.2 
mM Na3VO4, 1% NP-40, 1 mM PMSF, 1 mM 
DTT and 1x protease inhibitors (Roche)). 
Lysates were incubated with 1 µg of 
antibodies as indicated for 16h at 4°, 
antibodies were pulled down using Protein G 
Sepharose beads. For denaturing IPs, cells 
were subject to 20 µM of MG132 proteosomal 
inhibitor treatment for the final 16h followed 
by collection into lysis buffer with an addition 
of 2% SDS and denatured at 100°C for 10 
minutes [29]. Following denaturation samples 
were diluted 10x in lysis buffer without SDS 
and processed as in native IP. 
Immunoprecipitants were analysed using 
Western blotting. 
Chromatin immunoprecipitations (ChIP) were 
performed as described previously [10]. 
LNCaP cells were transfected in steroid-
depleted media for 72h followed by DHT 
treatment for 120 minutes. Data is presented as 
% Input using the following formula: % Input 
= 100 x 2^(CT Adjusted Input sample - CT 
immunoprecipitated sample), CT refers to 
cycle threshold. 
Immunohistochemistry (IHC) - Tissue 
microarray (TMA) containing 0.6-mm cores of 
benign prostatic hyperplasia (BPH) (n=7), PCa 
(n=7) and control tissues including breast, 
kidney, placenta, ovary and liver was used. 
Antigens were retrieved by pressure cooking 
the TMA in 0.01M Citrate buffer pH 6.0 
followed by staining the tissues with rabbit 
polyclonal anti-Usp12 antibody (Dundee Cell 
Products) [29].  
RESULTS 
Identification of Usp12 as a positive regulator 
of AR  - To identify DUBs that regulate AR we 
conducted an siRNA screen in LNCaP cells 
using an ELISA detecting the levels of 
Prostate Specific Antigen (PSA), which is an 
AR target gene product and as such its levels 
will be affected by any change in AR activity, 
as a surrogate readout of AR activity. All 
samples were normalised against the 
scrambled control (SCR) and readouts of +/- 
two fold PSA protein level compared to SCR 
were taken for further validation. To confirm 
that target DUBs regulate AR transcriptional 
activity and not only PSA secretion, further 
validation included the assessment of PSA 
mRNA levels upon DUB depletion eliminating 
DUBs that solely affect PSA rather than AR 
activity. Of the seventy-eight screened DUBs, 
four were identified as potentially involved in 
androgen-dependant regulation of AR. 
Silencing of one of the targets, Usp12, resulted 
in 73% reduction in PSA protein levels (fig 
1A, highlighted panel). This result was also 
confirmed by Western blotting (fig 1B). Usp12 
siRNA was shown to significantly decrease 
Usp12 transcript levels in three PCa cell lines 
namely, LNCaP, LNCaP-AI and VCaP (fig 
1C). Additionally depletion of Usp12 resulted 
in significant decrease of PSA transcript in 
LNCaP, LNCaP-AI and VCaP cells 
confirming that Usp12 affects AR 
transcriptional activity and as a result PSA 
gene expression rather than protein secretion 
(fig 1C). To summarise, Usp12 has been 
identified as a positive regulator of AR in 
multiple PCa cell lines and it was selected for 
further validation and analysis. 
Usp12 stabilises AR at the protein level - 
Ubiquitination of AR causes a change in AR 
activity and stability and impacts both survival 
and growth of PCa cells, as a result 
deubiquitination of those sites has an equally 
important role. We hypothesised that Usp12 
affects AR activity by deubiquitinating it and 
as a result stabilising AR protein. To 
determine the effects of Usp12 on AR activity 
and protein stability we analysed the levels of 
endogenous AR in PCa cells depleted of 
Usp12. Silencing of Usp12 resulted in a 
decrease of AR protein compared to SCR in 
three PCa cell lines (fig 2A-2C). Stabilisation 
of AR by Usp12 relies on enzymatic activity 
of this DUB as mutant Usp12C48A was not able 
to stabilise AR protein levels to the same 
extent as the wild type (fig 2D). Additionally 
as little as 1:10 of Usp12 (50ng) to AR 
(500ng) was sufficient to cause this effect (fig 
2D). Similarly when HEK293T cells were 
Usp12 is a novel positive regulator of the AR 
 
5 
 
transfected with AR and co-transfected with 
Usp12, Uaf-1 and WDR20 the levels of AR 
increased compared to AR alone (fig 2E). 
Even the increase in AR protein levels 
observed in cells transfected with Uaf-1 and 
WDR20 can be attributed to the stabilisation 
of endogenous Usp12 caused by the 
overexpression of its cofactors as illustrated by 
Usp12 protein levels (figure 2E). To assess if 
reduced receptor levels were a consequence of 
compromised AR gene expression we analysed 
AR transcript level in LNCaP cells depleted of 
Usp12. Knockdown of Usp12 or either one of 
its interacting partners had no statistically 
significant effect on AR transcript levels 
suggesting that Usp12 may function to 
enhance the stability of the AR in PCa cells 
(data not shown). Additionally, we 
investigated the effects of Usp12 depletion on 
AR half-life in PCa cells. In cells with 
depleted Usp12 the pool of AR was smaller 
than in controls even before the cycloheximide 
treatment and there was a trend of decreased 
half-life of AR (fig 2F). In conclusion we have 
shown that Usp12, with its interacting partners 
Uaf-1 and WDR20, increases AR protein 
levels rather than regulating its gene 
expression.  
AR stabilisation by Usp12 results in increased 
AR activity - To assess the effects of increased 
AR protein stability HEK293T cells were 
transfected with an androgen-responsive 
luciferase reporter containing three adjacent 
Androgen Responsive Elements (AREs) 
upstream from the luciferase gene. 
Additionally, combinations of mammalian 
expression vectors including dual Flag-AR, 
Flag-Usp12 and Flag-Uaf-1 were co-
transfected and receptor activity was assessed. 
Cells transfected with Usp12 showed a trend 
of increased AR transcriptional activity which 
was not statistically significant (fig 3A) 
however, when Usp12 and Uaf-1 were co-
transfected, AR transcriptional activity was 
significantly increased to levels comparable to 
that caused by the known AR co-regulator 
p300 (fig 3A). This result is in agreement with 
previous reports that Usp12 requires the 
presence of Uaf-1 for its enzymatic activity 
[27]. To confirm a transcriptional co-
regulatory role of Usp12 in the AR signalling 
cascade, we assessed AR activity upon 
depletion of Usp12 in the LNCaP variant cell 
line, LNCaP-7B7, which have a stably 
integrated luciferase gene under the control of 
the PSA promoter. Usp12 silencing caused a 
significant decrease in AR transcriptional 
activity both in steroid depleted conditions and 
after DHT stimulation (fig 3B). Additional 
confirmation of Usp12 effects on AR 
transcriptional activity came from qPCR 
analysis, where we observed that Usp12 
silencing caused a significant decrease of 
transcript levels of AR regulated genes PSA 
and TMPRSS2 (fig 3C and 1C) in multiple PCa 
cell lines. Further analysis of Usp12 silencing 
in LNCaP cells cultured in steroid depleted 
conditions followed by DHT stimulation for 0-
48h showed a significant decrease in transcript 
levels of all five androgen regulated genes that 
were tested (fig 3D). Our results confirm that 
the stabilisation of AR caused by Usp12 
results in enhanced transcriptional activity of 
AR and increased transcript levels of AR 
regulated genes. To determine the underlying 
cause of the decreased transcriptional activity 
of AR we performed ChIP analysis of AR 
recruitment to AREIII of PSA enhancer after 
DHT stimulation. AR recruitment was shown 
to be significantly decreased after Usp12 
silencing in comparison to SCR treated control 
further confirming the role of Usp12 in the 
regulation of AR activity (fig 3E). 
Stabilisation of AR by Usp12 affects survival 
and proliferation of prostate cells - We have 
shown that Usp12 enhances AR activity by up-
regulating receptor stability. We next assessed 
the role of Usp12 in regulating the survival 
and proliferation of PCa cell lines. 
Proliferation of three PCa cell lines was 
quantified by cell counting 96h post Usp12 
depletion. It was observed that Usp12 
silencing caused significant decrease in 
cellular proliferation in all three cell lines (fig 
4A). To examine the impact of Usp12 
knockdown on LNCaP cell survival, we 
measured apoptosis by Annexin V staining by 
flow cytometry. Silencing of the Usp12 
complex and Usp12 alone resulted in a 
significant increase of apoptotic cells that was 
comparable to the value obtained for cells with 
depleted AR (fig 4B). 
Cell cycle analysis by propidium iodine 
staining revealed that depletion of the Usp12 
complex results in a significant increase of G1 
arrested PCa cells (fig 4C). Additionally, 
silencing of the Usp12 complex significantly 
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increased the number of cells in subG1 phase 
confirming that it causes an increase in cellular 
apoptosis (fig 4D). 
One of the crucial properties of cancer cells is 
their ability to form colonies which allows for 
cancer survival. We evaluated the ability of 
LNCaP cells to form colonies after depletion 
of Usp12. Cells with silenced Usp12 had a 
significantly decreased ability to form colonies 
in comparison to SCR treated control (fig 4E). 
In conclusion, we have shown that AR 
stabilisation by Usp12 has a significant effect 
on proliferation and survival of PCa cells. 
Usp12 is pro-proliferative and cells deficient 
in it have decreased ability to proliferate, 
increased apoptosis, G1 arrest and are 
deficient in their ability to form colonies. This 
data suggests that Usp12 has a key role in PCa 
disease progression. 
Usp12 interacts with AR and stabilises it via 
deubiquitination  - We have shown that Usp12 
stabilises AR at the protein level and as a 
result increases transcriptional activity acting 
in a pro-survival manner in prostate cells. To 
determine if Usp12 interacts with AR we 
immunoprecipitated AR and its interacting 
partners from the whole cell lysate. These 
immunoprecipitants were immunoblotted for 
the presence of Usp12. Both wild type Usp12 
and its Cys48 catalytically deficient mutant 
Usp12C48A were shown to directly interact with 
AR (fig 5A). Additionally, we confirmed the 
interaction between the endogenous AR and 
Usp12 proteins in LNCaP PCa cells (fig 5B). 
To determine if this interaction affects the AR 
ubiquitination status we transfected COS-7 
cells with ubiquitin, AR and wild type and the 
deubiquitinase dead C48A mutant Usp12. 
Cells were treated with proteosomal inhibitors 
and lysed under denaturing conditions which 
ensures that only covalent bonds will remain 
unaffected and as a result only direct 
ubiquitination of the AR rather than its 
interacting partners can be visualised. Lysates 
were subsequently immunoprecipitated using 
an anti-ubiquitin antibody which allowed 
separation of all directly ubiquitinated proteins 
and the levels of ubiquitinated AR visualised 
by immunoblotting the precipitant for AR 
protein. Wild type but not Cys48 deficient 
mutant of Usp12 caused deubiquitination of 
AR (fig 5C).  
To assess potential co-localisation of the AR 
and Usp12 both proteins were ectopically 
expressed in COS-7 cells. 
Immunofluorescence and confocal microscopy 
were employed to visualise their cellular 
localisation. It was observed that Usp12 and 
AR co-localise in the cytoplasm in steroid 
depleted conditions (fig 5D). We have shown 
that enhanced levels of Usp12 result in 
increased AR protein stability and 
transcriptional activity. To confirm if this 
increase in Usp12 can be observed in vivo we 
analysed Usp12 positivity in benign and PCa 
patient samples. Usp12 protein levels were 
increased in PCa samples compared to benign 
controls (fig 5E). To summarise, AR and 
Usp12 interact and enzymatically functional 
Cys48 of Usp12 is not required for this 
interaction. Usp12 deubiquitinates AR through 
this interaction and for this intact Cys48 of 
Usp12 is required, as a result AR is stabilised 
at the protein level and its transcriptional 
activity is enhanced resulting in the activation 
of pro-survival pathways in prostate cells. 
DISCUSSION 
It is widely accepted that the post-translational 
regulation of AR protein stability is a crucial 
mechanism that regulates both normal and 
malignant prostate cells. Even in CRPCa AR 
still plays a major role and remains the main 
focus of therapeutic strategies, highlighting its 
importance as a drug target. Therapies aimed 
at AR invariably fail as a result of AR 
becoming promiscuous through mutations and 
acquiring the ability to become activated by a 
variety of steroid based ligands as well as 
antiandrogens [2]. As a result more focus is 
needed on upstream co-regulators of AR as 
they could be potential drug targets.  
Our study identified Usp12 as a novel positive 
regulator of AR through an siRNA screen of 
DUBs. Usp12 was initially identified as a 
histone H2B and H2A deubiquitinase [25, 23], 
recently it was also reported to be a negative 
regulator of Notch signalling by impairing 
Notch trafficking and decreasing its cell 
surface levels [24]. Still little is known about 
the role of Usp12 in humans but the role of the 
Usp12 homologue in yeast has been 
researched in more detail with the enzyme 
shown to be involved in actin dynamics, cell 
polarity and endocytosis [28]. In S. pombe, 
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silencing of the Usp12 homologue in 
combination with Myosin-1 or Wiskott-
Aldrich Syndrome protein (WAS) was 
reported to be lethal. Our data also points to 
the importance of Usp12 in cell survival as 
Usp12 depletion significantly increased the 
percentage of apoptotic cells and caused G1 
arrest in PCa cells suggesting an evolutionarily 
conserved role of Usp12 in cell survival. 
Usp12 DUB activity was previously shown to 
be very low in the absence of its binding 
partners, WD40 proteins Uaf-1 and WDR20 
[27]. Our reporter gene assays confirm this 
role of Uaf-1, we have shown that without 
Uaf-1, Usp12 was not able to increase AR 
transcriptional activity while Usp12 
knockdown alone was sufficient to decrease it. 
This confirms the role Uaf-1 plays in 
regulating the activity of Usp12. In S. pombe, 
binding partners were shown to be necessary 
not only for DUB activity but also to affect 
cellular localisation of Usp12. Uaf-1 deletion 
traps Usp12 in the nucleus and analogously 
WDR20 deletion traps Usp12 in the cytoplasm 
[28]. It remains to be established if their role in 
Usp12 localisation is conserved in human.    
DUBs have been previously shown to affect 
AR stability. Usp10 is reported to bind to AR 
and positively regulate its transcriptional 
activity [22]. Recently Usp10 effects on AR 
were proposed to be indirect via Usp10 
mediated deubiquitination of H2A.Z leading to 
transcriptional activation of AR [35]. This 
hypothesis requires further investigation in the 
context of Usp12 as it was also shown to 
deubiquitinate histones H2A and H2B [23]. It 
is possible that Usp12 effect on AR could be a 
combination of both direct deubiquitination 
and stabilisation of the receptor and indirect 
regulation through deubiquitination of histones 
which allows transcriptional activation. 
Similarly, Usp26 is reported to assemble with 
AR and additional cofactors in subnuclear foci 
resulting in AR deubiquitination [21]. We 
have also observed that Usp12 and AR 
colocalise and interact resulting in 
deubiquitination of AR. Co-localisation of AR 
and Usp12 occurs in the cytoplasm which can 
be explained by the large portion of the 
proteasome being present in the cytoplasm, it 
is also possible that for their co-localisation in 
the nucleus additional Usp12 co-factors would 
need to be co-transfected to facilitate its 
shuttling similarly to what was observed in S. 
pombe. This causes stabilisation of AR at a 
protein level. It has been previously published 
that silencing of AR results in G1 arrest and 
increased apoptosis, interestingly we have 
observed that Usp12 silencing has the same 
effects on PCa cells. These cellular effects 
might be mediated by a combination of both 
AR-mediated and AR-unrelated effects. AR 
stabilisation by Usp12 enhances transcriptional 
activity of AR and as a result increases cellular 
proliferation. We report that Usp12 acts in a 
pro-proliferative manner in PCa cells, this 
suggests that Usp12 may play a crucial role in 
prostate cancer development, progression and 
metastasis. It remains to be established if 
mutations in Usp12 that are associated with 
PCa occurrence and progression. Detailed 
impact of Usp12 in PCa and its potential as a 
therapeutic target need further assessment in 
the future.
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FIGURE LEGENDS 
FIGURE 1 Usp12 is a co-regulator of AR as shown by an siRNA screen 
(A) Results of the siRNA screen on the effects of DUBs knock down on AR activity presented as a 
readout of PSA protein levels measured by an ELISA in LNCaP cells. (B) LNCaP cells were treated 
with siRNA as indicated for 48h prior to DHT stimulation for 0-72 hours as indicated followed by 
lysis and immunoblotting. (C) LNCaP, LNCaP-AI and VCaP cells were treated with siRNA as 
indicated for 96h. Total RNA was extracted and quantitative RT-PCR performed to analyse the 
transcript levels of Usp12 and PSA normalised to HPRT1. Data are presented as mean +/- SEM of 
three independent experiments normalised to scrambled (SCR), statistical significance was analysed 
using t-test.  
 
FIGURE 2 Usp12 stabilises AR at the protein level 
(A-C) LNCaP, LNCaP-AI and VCaP cells respectively, were treated with siRNA as indicated. LNCaP 
and VCaP cells were cultured in full media and LNCaP-AI in DCC. At 96h cells were lysed followed 
by immunoblotting. (D) COS-7 cells were transfected with 500 ng of p-Flag-His-AR and increasing 
amounts (10-500 ng) of Wt and C48A mutant Usp12 for 48h. Reactions were balanced with empty 
pCMV vector. (E) HEK293T cells were transfected with pFlag-His-AR, pFlag-Usp12, pFlag-Uaf-1 
and pHA-Flag-WDR20 plasmids as indicated, at 48h cells were lysed followed by Western blotting. 
(F) LNCaP cells were treated with siRNA as indicated for 96 hours followed by treatment with 1µM 
of cycloheximide for 0-4 hours. 
 
FIGURE 3 Stabilisation of AR by Usp12 results in increased transcriptional activity of AR 
(A) HEK293T cells were transfected with pARE3-luc, pCMV-β-gal, pFlag-AR pFlag-Usp12, and 
pFlag-Uaf-1 as indicated and cultured for 48h in steroid depleted conditions followed by addition of 
DHT for 24h. Results are represented as a luciferase count per second normalised to β-galactosidase 
activity. Data are a mean +/- SEM of three independent experiments normalised to AR alone, 
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statistical significance was analysed with t-test. (B) LNCaP-7B7 cells were incubated in steroid-
depleted media followed by gene silencing after 24h. At 48h DHT was applied and luciferase quantity 
determined 48h later. Data was normalised to total protein content determined using a BCA assay. 
Data is displayed as the fold change in normalised luciferase activity compared to non-transfected 
cells without DHT treatment. Error bars represent SEM of three independent experiments. (C) 
LNCaP, LNCaP-AI and VCaP cells were treated with siRNA as indicated for 96h, total RNA was 
extracted and quantitative RT-PCR performed to analyse the transcript levels normalised to HPRT1. 
Data are a mean +/- SEM of three independent experiments normalised to SCR, statistical significance 
was analysed with t-test. (D) LNCaP cells were treated with siRNA for 48h followed by stimulation 
with DHT for 0-48h. Total RNA was extracted and quantitative RT-PCR performed to analyse the 
transcript levels normalised to HPRT1. Data are a mean +/- SEM of three independent experiments 
normalised to SCR, statistical significance was analysed using t-test. (E) LNCaP cells were treated 
with siRNA for 72h in steroid-depleted media. DHT was applied for 2h before cells were harvested 
and ChIP for AR recruitment to AREIII of PSA enhancer or control IgG performed. Data is 
represented as percentage recruitment relative to input and is the mean of three independent 
experiments +/- SEM.  
 
FIGURE 4 Stabilisation of AR by Usp12 affects prostate cancer cell survival and proliferation 
(A) LNCaP, LNCaP-AI and VCaP cells were treated with siRNA as indicated for 96h, following 
silencing cellular proliferation was assessed by cell counting and normalised to SCR. Data are a mean 
+/- SEM of three independent experiments, statistical analysis was undertaken with t-test; 
***p<0.001, *p<0.05. (B) LNCaP cells were treated with siRNA as indicated for 96h, following 
silencing levels of apoptotic cells were determined by flow cytometry detection of Annexin V positive 
cells and results were normalised to SCR. Data are a mean +/- SEM of four independent experiments, 
statistical analysis was undertaken with ANOVA test. (C) LNCaP cells were treated with siRNA as 
indicated for 96h, following silencing cell cycle status was determined by flow cytometry analysis of 
PI staining. Ratio of cells in G1 vs S phase was determined and results were normalised to SCR. Data 
are a mean +/- SEM of three independent experiments, statistical analysis was undertaken with 
ANOVA test. (D) LNCaP cells were treated with siRNA as indicated for 96h, following silencing the 
number of cells in subG1 phase was determined by flow cytometry analysis of PI staining. Results 
were normalised to SCR. Data are a mean +/- SEM of three independent experiments, statistical 
analysis was undertaken with ANOVA test. (E) LNCaP cells were treated with siRNA as indicated for 
72h, following silencing cells were seeded at equal numbers with varied densities in 6-well plates and 
incubated for 14 days. At day 14 cells were fixed and stained with crystal violet, number of colonies 
in each sample was determined and normalised to SCR. Data are a mean +/- SEM of three 
independent experiments, statistical analysis was undertaken with t-test. Images show growth 14 days 
after seeding 4,000 cells per 2mm well. 
 
FIGURE 5 Usp12 interacts with AR resulting in AR deubiquitination and AR stabilisation 
(A) HEK293T cells were transfected with plasmids as indicated, wild type (Usp12) and Cys48 
deficient mutant (Usp12M) of Usp12 were used. 48h post transfection cells were harvested and 
lysates were immunoprecipitated (IP) with 1µg of AR antibody followed by immunoblotting. (B) 
LNCaP cells were harvested and lysates immunoprecipitated for AR and with a non-specific IgG. (C) 
COS-7 cells were transfected with plasmids as indicated, wild type (Usp12) and Cys48 deficient 
mutant (Usp12M) of Usp12 were used. 72h post transfection cells were treated with MG132 and 
harvested 16h later. Lysates were denatured and subsequently immunoprecipitated (IP) with 1µg of 
Ubiquitin antibody followed by immunoblotting. (D) COS-7 cells were grown in steroid depleted 
media and transfected with equal amounts of Usp12-Flag and AR plasmids, 48h post transfection cells 
were fixed and immunofluorescence followed by confocal microscopy were used to visualise both 
proteins cellular localisation, DAPI was used as a nuclear stain. Scale bar = 20µm. (E) Usp12 
immunohistochemistry of PCa and benign patient samples. Images are representatives of n=7 for each 
group. Bar = 50µm. 
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